Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 4;7(9):1105-13.
doi: 10.7150/jca.14801. eCollection 2016.

The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis

Shiva Basnet  1 , Zhen-Yu Zhang  1 , Wen-Qiang Liao  1 , Shu-Heng Li  1 , Ping-Shu Li  2 , Hai-Yan Ge  1
Affiliations

The Prognostic Value of Circulating Cell-Free DNA in Colorectal Cancer: A Meta-Analysis

Shiva Basnet et al. J Cancer. .

Abstract

Background: Circulating cell-free DNA (cfDNA) is a promising candidate biomarker for detection, monitoring and survival prediction of colorectal cancer (CRC). However, its prognostic significance for patients with CRC remains controversial. To derive a precise estimation of the prognostic significance of cfDNA, a meta-analysis was performed.

Methods: We made a systematic search in data base of the Science Citation Index Embase and Pubmed for studies reporting prognostic data of cfDNA in CRC patients. The data of cfDNA on recurrences-free survival (RFS) and overall survival (OS) were extracted and measured in hazard rates (HRs) and 95% confident intervals (CIs). Subgroup analyses were carried out as well. Finally, the meta-analysis is accompanied with nine studies including 19 subunits.

Results: The pooled HRs with 95% CIs revealed strong associations between cfDNA and RFS (HR [95%CI]=2.78[2.08-3.72], I(2)=32.23%, n=7) along with OS (HR [95%CI]=3.03[2.51-3.66], I(2)=29.24%, n=12) in patients with CRC. Entire subgroup analyses indicated strong prognostic value of cfDNA irrespective tumor stage, study size, tumor markers, detection methods and marker origin.

Conclusions: All the results exhibits that appearance of cfDNA in blood is an indicator for adverse RFS and OS in CRC patients.

Keywords: Plasma DNA; cell-free DNA; colorectal cancer; meta-analysis.; prognosis.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors declare that they have no potential competing interests.

Figures

Figure 1
Figure 1
Study selection flow chart.
Figure 2
Figure 2
Forest plots of pooled effects for RFS (a) and OS (b) in CRC patients.
Figure 3
Figure 3
Funnel plots of publication bias for RFS (a) and OS (b) in CRC patients.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: a cancer journal for clinicians. 2015;65:5–29. - PubMed
    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65:87–108. - PubMed
    1. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. Journal of the National Cancer Institute. 2004;96:1420–5. - PubMed
    1. Moon SH, Kim DY, Park JW, Oh JH, Chang HJ, Kim SY. et al. Can the new American Joint Committee on Cancer staging system predict survival in rectal cancer patients treated with curative surgery following preoperative chemoradiotherapy? Cancer. 2012;118:4961–8. - PubMed
    1. Gion M, Mione R, Barioli P, Dittadi R. Dynamic use of tumor markers, rationale-clinical applications and pitfalls. Anticancer research. 1996;16:2279–84. - PubMed

LinkOut - more resources